An earlier study [65] investigated the possible reasons behind failed anti-PD-1 (nivolumab) treatment in patients where high PD-L1 expression (≥ 5% of tumor cell surface staining) was observed by immunohistochemical staining (IHC). Here, PDCD1 is linked to neoplasm.